MUCOLINC
Brand:
MUCOLINC
Manufacturer:
CIPLA
Manufacturer Details
CIPLA
Compositions:
Bromexhine 8mg+ Sabutamol 2mg tablets,
Bromhexine 4mg + Salbutamol 2mg per 5ml EXPECTORANT,
|
Strength
|
Rate
|
Packing Style
|
|
4mg+2mg
|
24.04
|
10s tablets
|
|
4mg+ 2mg per 5ml
|
68.50
|
100ml EXPECTORANT
|
List of Related Indications:
- Bronchospasm in asthma
- Chronic bronchitis
- Emphysema
List Of Drugs:
- Salbutamol Sulphate @ - Sympathomim- Bronchodilators- (FDC- List )- (Mar 2000)
Indication Type Description:
Pharmacology/ Pharmacokinetics
Drug Interaction:
Beclomethasone or theophylline enhance respiratory function. Beta-blockers inhibit the bronchodilator effect of sympathomimetic bronchodilators. Diuretics and xanthines may augument hypokalemia, increased susceptibility to digitalis toxicity in high dose to hypokalaemia.
Indication:
Prevention of bronchial apasms in patients with reversible airways disease.
FIXED DOSE COMBINATIONS APPROVED BY DCG(I)
FROM JANUARY 1961 TILL NOVEMBER 2014
Name of Drug Indication Date of Approval
Salbutamol sulphate eq.to 06-03-2000
Salbutamol 100mg +
Ibratropium Bromide BP 200mcg inhaler
In the treatment of chronic obstructive pulmonary
disease
Adverse Reaction:
None reported excepting occasional reports of ischemia. Fine skeletal muscle tremor (esp hands), tachycardia, palpitations, peripheral vasodilatation, hypotension, nausea, headache, hypokalemia. I/V administration: In high doses (to delay premature labour) nausea, vomiting, adverse cardiac and metabolic effects. Inhalation of dry powder: Slight cough and irritation.
Contra-Indications:
Thyrotoxicosis, hypersens.
Special precautions:
Care in patients who have received large doses of other sympathomimetic drugs. Caution in thyrotoxicosis patients. To be used with respirator or nebuliser only, and under the direction of a physician. Not to be injected or given orally. Dose or fequency of administration should not be increased, if relief or its duration is diminished. Pregnancy, Elderly (increased chances of angina, arrhythmias and urinary retention).
Dosages/ Overdosage Etc:
Date of approval- 2000
Indications:
Prevention of bronchial apasms in patients with reversible airways disease.
Dosage:
Inhalation aerosols- Adults and children above 12 years- 2 inhalations repeated every 4 to 6 hours. In some patients 1 inhalation every 4 hours may be sufficient. More frequent inhalatios or larger number of inhalations not recommended.
Patient Information:
1. Do not exceed the recommended dosage, excessive use may lead to adverse effect or loss of effectiveness.
2. Do not stop or adjust the dose.
3. Do not change brands without consulting the physician or the pharmacist.
4. If more than one inhaltion is necessary,wait for at least one full minute between inhalitions (administer the second inhalation at 3 to 5 minutes for isoproternol and epinephrine, 2 minutes for metoproternol ).
5. Notify physician of failure to respond to usual dosage or of dizziness or chest pain.
6. Isopreternol may cause the patients saliva to turn pinkish-red.
Pharmacology/ Pharmacokinetics:
Refer sympathomimetics- bronchodilators
Interaction with Food:
Refer sympathomimetics - bronchodilators
Pregnancy and lactation:
Pregnancy, Elderly (increased chances of angina, arrhythmias and urinary retention).
